The DEEP project has received research funding from the European Union under the 7th Framework Programme
DEEP-3 is a long-term observational safety study which evaluates the nature and incidence of adverse effects of deferiprone (DFP) in children and adolescents with beta-thalassaemia major and currently involves 18 recruiting centres from 7 different countries: Albania, Cyprus, Greece, Egypt, Italia, Morocco and Tunisia.
On […]
The first two groups of paediatric patients enrolled at the DEEP-2 Albanian experimental site in Tirana (University Hospital Centre “Mother Teresa”) has performed the MRI scans as per DEEP-2 Study Protocol. Children have been accompanied by the Trial Medical Staff to Athens, where the radiology is […]
The DEEP-1 pharmacokinetic study evaluated the systemic exposure of DFP in the paediatric population aged from 1 month to < 6 years for which PK profile of deferiprone is unknown. This lack of information implies that so far the dosage of deferiprone in this age subset can […]
On the 2nd of January 2015, the Azienda Ospedaliera di Padova (AOSP) has enrolled its first patient in the DEEP-2 study (multicentre, randomized, open label, controlled trial aimed at comparing the efficacy of deferiprone and deferasirox in paediatric patients). Other two paediatric patients have been included in […]
